Drug Trial Radar · NCT06415344
Long-term Extension of GTX-102 in Angelman Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
66
Actual
Start
Jul 31, 2024
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- May 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)
Conditions
- Angelman Syndrome
Interventions
GTX-102Drug
Antisense Oligonucleotide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 5 Years
Locations
23 sites in 8 countries. Site status is shown where the registry gives one.
University of California, Los Angeles (UCLA)
Los Angeles, California
University of California, San Diego - Rady Children's Hospital
San Diego, California
Rare Disease Research, LLC
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
Boston Children's Hospital
Boston, Massachusetts
Weill Cornell Medicine
New York, New York
Queensland Children's Hospital
South Brisbane, Queensland, Australia
The Royal Children's Hospital
Melbourne, Victoria, Australia
MAGIC Clinic Ltd
Calgary, Alberta, Canada
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Childrens Hospital London Health Sciences Centre
London, Ontario, Canada
Childrens Hospital of Eastern Ontario
Ottawa, Ontario, Canada
The Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada
AP-HM - Hopital de la Timone
Marseille, France
AP-HP Hopital Necker-Enfants Malades
Paris, France
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitaetsklinikum Leipzig
Leipzig, Germany
Sheba Medical Center
Ramat Gan, Israel
Hospital Universitario Puerta de Hierro
Majadahonda, Spain
Corporacio Sanitaria Parc Tauli - Hospital de Sabadell
Sabadell, Spain
University of Cambridge
Cambridge, United Kingdom
Great Ormond Street Hospital for Children
London, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.